Orchestra BioMed to Present at Upcoming Investor Conferences

Company Overview - Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies [4] - The company's lead product candidate is atrioventricular interval modulation (AVIM) therapy for treating hypertension, a significant global health risk [4] - Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for treating atherosclerotic artery disease, which is the leading cause of mortality worldwide [4] Strategic Partnerships - The company has a strategic collaboration with Medtronic for the development and commercialization of AVIM therapy in pacemaker-indicated patients [4] - Additionally, Orchestra BioMed has partnered with Terumo for the development and commercialization of Virtue SAB for artery disease treatment [4] Upcoming Investor Engagements - Company management will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 2:30 PM ET [2] - A fireside chat is scheduled at the Barclays 27th Annual Global Healthcare Conference on March 13, 2025, at 8:00 AM ET [2] - The company will also host one-on-one meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025 [3]